NextCure Announces Presentations on Targets in Development by Collaborators at American Society of Hematology Annual Meeting

Rhea-AI Summary

NextCure, Inc. (NXTC) announced it will present new data from two studies at the 63rd American Society of Hematology annual meeting from December 11-14, 2021. The studies focus on the role of Siglec-15 in childhood leukemia and the effects of LAIR-1 monoclonal antibodies in acute myeloid leukemia, in collaboration with Emory and Vanderbilt Universities. These findings aim to advance the understanding and treatment of these cancers, specifically for patients not adequately addressed by existing therapies.

Positive

• Presentation of new data at a prominent medical conference may enhance visibility and credibility.
• Focus on innovative treatment strategies targeting childhood leukemia and acute myeloid leukemia aligns with unmet medical needs.

Negative

• The company has no products approved for commercial sale, indicating ongoing developmental risks.
• NextCure has a history of significant losses and requires additional financing for its operations.

BELTSVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that new data from two research studies will be presented during oral and poster sessions at the 63^rd annual American Society of Hematology (ASH) annual meeting, to be held in Atlanta, Georgia and in a virtual platform on December 11-14, 2021.

The data come from research studies evaluating the role of Siglec-15 (S15) in B cell acute lymphoblastic leukemia (B-ALL) and potential to target S15 in childhood leukemia in collaboration with Emory University, and the impact of LAIR-1 expression on acute myeloid leukemia (AML) blasts and the use of LAIR-1 monoclonal antibodies in AML in collaboration with Vanderbilt University.

Details related to the poster presentations are as follows:

Title: Siglec-15 is a Novel Immunomodulatory Protein and Therapeutic Target in Childhood Leukemia
Presenting Author: Claire E. Pillsbury, Emory University School of Medicine
Abstract Number: 515
Session Name: 614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies II
Session Date: Sunday, December 12, 2021
Session Time: 4:30 PM - 6:00 PM
Presentation Time: 5:30 PM

Title: A Novel LAIR-1 antibody selectively targets AML stem cells
Presenting Author: Tae Kon Kim, Vanderbilt University School of Medicine
Abstract Number: 3413
Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
Session Date & Time: Monday, December 13, 2021
Session Time: 6:00 PM - 8:00 PM

About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.com

Cautionary Statement Regarding Forward-Looking Statements
Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure’s plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com

FAQ

What studies will NextCure present at the ASH annual meeting 2021?

NextCure will present studies on Siglec-15's role in childhood leukemia and LAIR-1 monoclonal antibodies in acute myeloid leukemia.

When is the ASH annual meeting 2021?

The ASH annual meeting will take place from December 11-14, 2021.

What is the significance of the data presented by NextCure at ASH?

The data may provide insights into innovative treatments for cancers with unmet needs.

Does NextCure have approved products in the market?

No, NextCure currently has no products approved for commercial sale.

What financial challenges does NextCure face?

NextCure has significant losses and needs additional financing for operations.